X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (1547) 1547
Publication (111) 111
Book Review (16) 16
Book Chapter (5) 5
Conference Proceeding (4) 4
Dissertation (1) 1
Magazine Article (1) 1
Web Resource (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (1223) 1223
index medicus (1028) 1028
male (578) 578
pyridones - therapeutic use (574) 574
animals (534) 534
pyridones - pharmacokinetics (502) 502
pyridones - pharmacology (481) 481
female (447) 447
pyridones - administration & dosage (435) 435
pharmacology & pharmacy (396) 396
administration, oral (370) 370
pyridones - adverse effects (311) 311
rivaroxaban (279) 279
pharmacokinetics (258) 258
dabigatran (251) 251
adult (250) 250
middle aged (249) 249
pyrazoles - therapeutic use (235) 235
pyridones - chemistry (233) 233
rats (233) 233
apixaban (227) 227
anticoagulants (226) 226
aged (220) 220
anticoagulants - therapeutic use (189) 189
treatment outcome (188) 188
dose-response relationship, drug (183) 183
pyrazoles - administration & dosage (180) 180
chemistry, medicinal (169) 169
mice (168) 168
warfarin (160) 160
anticoagulants - administration & dosage (149) 149
hematology (149) 149
pyrazoles - adverse effects (149) 149
analysis (143) 143
venous thromboembolism (137) 137
pyridones - blood (135) 135
anticoagulants - adverse effects (134) 134
safety (130) 130
pyrazoles - pharmacokinetics (127) 127
structure-activity relationship (124) 124
atrial fibrillation (123) 123
beta-alanine - analogs & derivatives (123) 123
drug therapy (118) 118
morpholines - therapeutic use (117) 117
atrial fibrillation - drug therapy (115) 115
deferiprone (115) 115
thiophenes - therapeutic use (112) 112
stroke - prevention & control (109) 109
efficacy (108) 108
hemorrhage - chemically induced (108) 108
prevention (108) 108
adolescent (105) 105
double-blind (104) 104
atrial-fibrillation (103) 103
benzimidazoles - therapeutic use (103) 103
medicine & public health (102) 102
pyridones - chemical synthesis (100) 100
care and treatment (99) 99
factor xa inhibitors (98) 98
pyrazoles - pharmacology (97) 97
biochemistry & molecular biology (96) 96
factor xa inhibitor (96) 96
research (95) 95
young adult (94) 94
atrial fibrillation - complications (93) 93
dabigatran etexilate (93) 93
oncology (93) 93
toxicology (93) 93
anticoagulants - pharmacokinetics (90) 90
stroke (89) 89
rats, sprague-dawley (88) 88
thromboembolism (88) 88
cardiac & cardiovascular systems (86) 86
therapy (85) 85
chemistry, organic (83) 83
in-vitro (82) 82
cancer (80) 80
pyridines - therapeutic use (80) 80
drug therapy, combination (79) 79
thrombin (79) 79
warfarin - therapeutic use (79) 79
aged, 80 and over (78) 78
cell line, tumor (78) 78
double-blind method (78) 78
peripheral vascular disease (78) 78
clinical trials (77) 77
drug interactions (77) 77
molecular structure (77) 77
pirfenidone (76) 76
beta-alanine - therapeutic use (75) 75
milrinone (75) 75
time factors (75) 75
pharmacodynamics (74) 74
pyridones - metabolism (74) 74
iron chelating agents - therapeutic use (73) 73
dosage and administration (72) 72
morpholines - administration & dosage (71) 71
half-life (70) 70
article (69) 69
risk factors (69) 69
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (1510) 1510
German (17) 17
French (6) 6
Japanese (5) 5
Spanish (5) 5
Italian (3) 3
Chinese (1) 1
Danish (1) 1
Polish (1) 1
Swedish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


JACC (Journal of the American College of Cardiology), ISSN 0735-1097, 2016, Volume 67, Issue 24, pp. 2888 - 2899
Abstract Nonvitamin K-dependent oral anticoagulant agents (NOACs) are currently recommended for patients with atrial fibrillation at risk for stroke. As a... 
Cardiovascular | Internal Medicine | dabigatran | rivaroxaban | apixaban | stroke | edoxaban | renal dialysis | CARDIAC & CARDIOVASCULAR SYSTEMS | APPENDAGE CLOSURE | PLATELET-AGGREGATION | SAFETY | PHARMACOKINETICS | PROTHROMBIN COMPLEX CONCENTRATE | ORAL ANTICOAGULANTS | HEMODIALYSIS-PATIENTS | NONVALVULAR ATRIAL-FIBRILLATION | STAGE RENAL-DISEASE | WARFARIN USE | Pyrazoles - therapeutic use | Dabigatran - pharmacokinetics | Humans | Pyridines - pharmacokinetics | Renal Insufficiency, Chronic - complications | Thiazoles - therapeutic use | Dabigatran - therapeutic use | Thiazoles - pharmacokinetics | Warfarin - therapeutic use | Renal Insufficiency, Chronic - therapy | Kidney - metabolism | Pyrazoles - pharmacokinetics | Rivaroxaban - therapeutic use | Pyridines - therapeutic use | Stroke - prevention & control | Glomerular Filtration Rate | Pyridones - pharmacokinetics | Atrial Fibrillation - drug therapy | Anticoagulants - therapeutic use | Creatinine - urine | Warfarin - pharmacokinetics | Kidney Failure, Chronic - therapy | Rivaroxaban - pharmacokinetics | Kidney Failure, Chronic - complications | Anticoagulants - pharmacokinetics | Pyridones - therapeutic use | Hemorrhage - chemically induced | Renal Dialysis | Stroke (Disease) | Medical colleges | Care and treatment | Continuing medical education | Warfarin | Chronic kidney failure | Atrial fibrillation | Mortality | Medical care | Quality management | Urine | Confidence intervals | Disease prevention | Anticoagulants | Stroke | Hemodialysis | Kidney diseases | Metabolism | Drug dosages
Journal Article
The Journal of Clinical Pharmacology, ISSN 0091-2700, 05/2016, Volume 56, Issue 5, pp. 628 - 636
Journal Article
Clinical Pharmacokinetics, ISSN 0312-5963, 4/2013, Volume 52, Issue 4, pp. 243 - 254
The direct factor Xa (FXa) inhibitors rivaroxaban, apixaban and edoxaban, and the thrombin inhibitor dabigatran etexilate (dabigatran) have gained approval for... 
Pharmacotherapy | Internal Medicine | Medicine & Public Health | Pharmacology/Toxicology | UNITED-STATES | IN-VITRO | BAY-59-7939 | VENOUS THROMBOEMBOLISM | PHARMACOKINETICS | SAFETY | COAGULATION DISORDERS | PHARMACOLOGY & PHARMACY | PHARMACODYNAMICS | STAGE LIVER-DISEASE | RENAL IMPAIRMENT | Thiophenes - therapeutic use | Pyrazoles - therapeutic use | Anticoagulants - administration & dosage | Factor Xa Inhibitors | Humans | Thrombin - antagonists & inhibitors | Pyridines - pharmacokinetics | Metabolic Clearance Rate | Thiazoles - administration & dosage | Thiophenes - administration & dosage | Dabigatran | Thiazoles - therapeutic use | Thiazoles - pharmacokinetics | Venous Thromboembolism - blood | Dose-Response Relationship, Drug | Tissue Distribution | Pyridones - administration & dosage | Rivaroxaban | Venous Thromboembolism - prevention & control | Absorption | Benzimidazoles - administration & dosage | Venous Thromboembolism - complications | Liver Diseases - complications | Pyrazoles - pharmacokinetics | Morpholines - therapeutic use | Benzimidazoles - therapeutic use | Pyridines - therapeutic use | Pyridines - administration & dosage | Pyridones - pharmacokinetics | Morpholines - administration & dosage | Benzimidazoles - pharmacokinetics | Anticoagulants - therapeutic use | Thiophenes - pharmacokinetics | Pyrazoles - administration & dosage | Anticoagulants - pharmacokinetics | Pyridones - therapeutic use | Morpholines - pharmacokinetics | Liver Diseases - metabolism | Prevention | Physiological aspects | Usage | Anticoagulants (Medicine) | Thromboembolism | Drug therapy
Journal Article
Journal Article
British Journal of Surgery, ISSN 0007-1323, 06/2014, Volume 101, Issue 7, pp. 742 - 749
Background New oral anticoagulants (NOACs) offer an alternative to warfarin for preventing stroke in patients with atrial fibrillation. NOACs are expected to... 
ENOXAPARIN | SURGERY | DIRECT THROMBIN INHIBITOR | DABIGATRAN ETEXILATE | WARFARIN | RIVAROXABAN | APIXABAN | THROMBOPROPHYLAXIS | FACTOR-XA | ATRIAL-FIBRILLATION | REVERSAL | Anticoagulants - administration & dosage | Humans | beta-Alanine - pharmacokinetics | Half-Life | Pyridines - pharmacokinetics | Biological Availability | Thiazoles - administration & dosage | Hemorrhage - prevention & control | Thiophenes - administration & dosage | Dabigatran | Drug Monitoring - methods | Thiazoles - pharmacokinetics | Warfarin - therapeutic use | Pyridones - administration & dosage | Rivaroxaban | Benzimidazoles - administration & dosage | Time Factors | Pyrazoles - pharmacokinetics | beta-Alanine - analogs & derivatives | Stroke - prevention & control | Pyridines - administration & dosage | Pyridones - pharmacokinetics | Administration, Oral | Morpholines - administration & dosage | Atrial Fibrillation - complications | beta-Alanine - administration & dosage | Benzimidazoles - pharmacokinetics | Emergencies | Clinical Trials as Topic | Preoperative Care | Thiophenes - pharmacokinetics | Medication Adherence | Pyrazoles - administration & dosage | Stroke - etiology | Anticoagulants - pharmacokinetics | Hemorrhage - chemically induced | Morpholines - pharmacokinetics | Elective Surgical Procedures | Care and treatment | Atrial fibrillation | Anticoagulants (Medicine)
Journal Article
Annals of oncology : official journal of the European Society for Medical Oncology, ISSN 0923-7534, 07/2017, Volume 28, Issue 7, pp. 1631 - 1639
Background: Previous analysis of COMBI-d (NCT01584648) demonstrated improved progression-free survival (PFS) and overall survival (OS) with combination... 
trametinib | melanoma | durable outcomes | BRAF | metastatic | dabrafenib | MULTICENTER | OPEN-LABEL | COMBINATION | TRIAL | MEK INHIBITION | ONCOLOGY | DOUBLE-BLIND | POOLED ANALYSIS | NIVOLUMAB | IPILIMUMAB | VEMURAFENIB | Skin Neoplasms - drug therapy | Oximes - pharmacokinetics | Oximes - adverse effects | Humans | Antineoplastic Combined Chemotherapy Protocols - pharmacokinetics | Oximes - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Imidazoles - administration & dosage | Imidazoles - pharmacokinetics | Protein Kinase Inhibitors - adverse effects | Pyridones - administration & dosage | Time Factors | Melanoma - genetics | Skin Neoplasms - mortality | Protein Kinase Inhibitors - pharmacokinetics | Skin Neoplasms - pathology | Double-Blind Method | Drug Administration Schedule | Pyridones - pharmacokinetics | Imidazoles - adverse effects | Pyrimidinones - adverse effects | Risk Factors | Kaplan-Meier Estimate | Treatment Outcome | Disease Progression | Melanoma - secondary | Disease-Free Survival | Protein Kinase Inhibitors - administration & dosage | Pyrimidinones - pharmacokinetics | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Proto-Oncogene Proteins B-raf - genetics | Melanoma - drug therapy | Skin Neoplasms - genetics | Biomarkers, Tumor - genetics | Pyrimidinones - administration & dosage | Mutation | Pyridones - adverse effects | Melanoma - mortality | Original
Journal Article
Journal Article